Skip to main content
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Original Paper

Factors influencing the willingness of US women to vaccinate their daughters against the human papillomavirus to prevent cervical cancer

verfasst von: Jennifer Y. Lai, Anna V. Tinker, Winson Y. Cheung

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The human papillomavirus (HPV) vaccine helps to prevent cervical cancer. However, research indicates that public acceptance of the vaccine is suboptimal. Our aims were to evaluate the willingness of US women to use the HPV vaccine in their daughters, examine their current understanding of HPV, and determine the impact of HPV knowledge and other socio-demographic factors on their willingness to get their daughters vaccinated. Women aged ≥18 years were identified from the US Health Information National Trends Survey. We developed a 6-point composite scoring system based on individual responses to HPV-related questions to characterize personal understanding about HPV. Logistic regression models were constructed to explore the influence of the women’s HPV knowledge level and additional socio-demographic factors on the willingness to use HPV in their daughters. There were 804 female respondents: mean age was 44.9 (SD = 2.53) years and 73 % were White. In total, 75 % of women indicated they would vaccinate their daughters against HPV. Mean knowledge score was 4.6 (SD = 0.80). While White race was associated with higher willingness to use the vaccine in their daughters (OR = 1.86, p = 0.04), HPV knowledge level was not (OR = 0.47, p = 0.22). Among US women, HPV knowledge level was high, but it was not associated with the willingness to vaccinate their daughters against HPV. Interventions focused on alleviating racial disparities might better modify the use of the HPV vaccine.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
3.
Zurück zum Zitat Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80:3812–5.PubMedCrossRef Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983;80:3812–5.PubMedCrossRef
4.
Zurück zum Zitat Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151–7.PubMed Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151–7.PubMed
5.
Zurück zum Zitat Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802.PubMedCrossRef Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802.PubMedCrossRef
6.
Zurück zum Zitat Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef
7.
Zurück zum Zitat Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.PubMedCrossRef Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.PubMedCrossRef
8.
Zurück zum Zitat Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303–15.PubMedCrossRef Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303–15.PubMedCrossRef
9.
Zurück zum Zitat Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.PubMedCrossRef Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.PubMedCrossRef
10.
Zurück zum Zitat Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072–9.PubMedCrossRef Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072–9.PubMedCrossRef
11.
Zurück zum Zitat Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.PubMedCrossRef Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.PubMedCrossRef
12.
Zurück zum Zitat Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–7.PubMedCrossRef Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–7.PubMedCrossRef
13.
Zurück zum Zitat Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology. 1992;190:548–52.PubMedCrossRef Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology. 1992;190:548–52.PubMedCrossRef
14.
Zurück zum Zitat Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993;67:1936–44.PubMed Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993;67:1936–44.PubMed
15.
Zurück zum Zitat Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.PubMedCrossRef Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.PubMedCrossRef
16.
Zurück zum Zitat The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.CrossRef The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.CrossRef
17.
Zurück zum Zitat Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70.PubMedCrossRef Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70.PubMedCrossRef
18.
Zurück zum Zitat Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–53.PubMedCrossRef Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–53.PubMedCrossRef
19.
Zurück zum Zitat Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15–44 years of age, United States. Adv Data. 2002;2005:1–55. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15–44 years of age, United States. Adv Data. 2002;2005:1–55.
20.
Zurück zum Zitat Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40:108–15.PubMedCrossRef Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40:108–15.PubMedCrossRef
21.
Zurück zum Zitat Bernat DH, Harpin SB, Eisenberg ME, Bearinger LH, Resnick MD. Parental support for the human papillomavirus vaccine. J Adolesc Health. 2009;45:525–7.PubMedCrossRef Bernat DH, Harpin SB, Eisenberg ME, Bearinger LH, Resnick MD. Parental support for the human papillomavirus vaccine. J Adolesc Health. 2009;45:525–7.PubMedCrossRef
22.
Zurück zum Zitat Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol. 2009;19:531–8.PubMedCrossRef Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol. 2009;19:531–8.PubMedCrossRef
23.
Zurück zum Zitat Jain N, Stokley S, Yankey MA. Centers for disease control and prevention. Vaccination coverage among adolescents aged 13–17 years-United States, 2007. MMWR2008:1100–1103. Jain N, Stokley S, Yankey MA. Centers for disease control and prevention. Vaccination coverage among adolescents aged 13–17 years-United States, 2007. MMWR2008:1100–1103.
24.
Zurück zum Zitat Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 2009. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 2009.
25.
Zurück zum Zitat Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009;45:453–62.PubMedCrossRef Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009;45:453–62.PubMedCrossRef
26.
Zurück zum Zitat Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010;171:357–67.PubMedCrossRef Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010;171:357–67.PubMedCrossRef
27.
Zurück zum Zitat Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health. 2009;45:528–31.PubMedCrossRef Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health. 2009;45:528–31.PubMedCrossRef
28.
Zurück zum Zitat Cantor DCK, Crystal-Mansour S, Davis T, Dipko S, Sigman R.: Health Information National Trends Survey (HINTS) 2007 Final Report. In: Rockville M, editor. Westat2009. Cantor DCK, Crystal-Mansour S, Davis T, Dipko S, Sigman R.: Health Information National Trends Survey (HINTS) 2007 Final Report. In: Rockville M, editor. Westat2009.
29.
Zurück zum Zitat Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45:107–14.PubMedCrossRef Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45:107–14.PubMedCrossRef
30.
Zurück zum Zitat Holcomb B, Bailey JM, Crawford K, Ruffin MTt. Adults’ knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract. 2004;17:26–31.PubMedCrossRef Holcomb B, Bailey JM, Crawford K, Ruffin MTt. Adults’ knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract. 2004;17:26–31.PubMedCrossRef
31.
Zurück zum Zitat Behbakht K, Lynch A, Teal S, Degeest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol. 2004;104:1355–61.PubMedCrossRef Behbakht K, Lynch A, Teal S, Degeest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol. 2004;104:1355–61.PubMedCrossRef
32.
Zurück zum Zitat Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the US know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007;16:288–94.PubMedCrossRef Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the US know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007;16:288–94.PubMedCrossRef
33.
Zurück zum Zitat Brownson RC, Jackson-Thompson J, Wilkerson JC, Davis JR, Owens NW, Fisher EB Jr. Demographic and socioeconomic differences in beliefs about the health effects of smoking. Am J Public Health. 1992;82:99–103.PubMedCrossRef Brownson RC, Jackson-Thompson J, Wilkerson JC, Davis JR, Owens NW, Fisher EB Jr. Demographic and socioeconomic differences in beliefs about the health effects of smoking. Am J Public Health. 1992;82:99–103.PubMedCrossRef
34.
Zurück zum Zitat Manderbacka K, Lundberg O, Martikainen P. Do risk factors and health behaviours contribute to self-ratings of health? Soc Sci Med. 1999;48:1713–20.PubMedCrossRef Manderbacka K, Lundberg O, Martikainen P. Do risk factors and health behaviours contribute to self-ratings of health? Soc Sci Med. 1999;48:1713–20.PubMedCrossRef
35.
Zurück zum Zitat Wynd CA. Smoking patterns, beliefs, and the practice of healthy behaviors in abstinent, relapsed, and recalcitrant smokers. J Vasc Nurs. 2007;25:32–8.PubMedCrossRef Wynd CA. Smoking patterns, beliefs, and the practice of healthy behaviors in abstinent, relapsed, and recalcitrant smokers. J Vasc Nurs. 2007;25:32–8.PubMedCrossRef
36.
Zurück zum Zitat Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003;30:774–8.PubMedCrossRef Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003;30:774–8.PubMedCrossRef
37.
Zurück zum Zitat Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188–94.PubMedCrossRef Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188–94.PubMedCrossRef
38.
Zurück zum Zitat Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS. 2003;14:300–6.PubMedCrossRef Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS. 2003;14:300–6.PubMedCrossRef
39.
Zurück zum Zitat Lemon SC, Rakowski W, Clark MA, Roy J, Friedmann PD. Variations in influenza vaccination among the elderly. Am J Health Behav. 2004;28:352–60.PubMedCrossRef Lemon SC, Rakowski W, Clark MA, Roy J, Friedmann PD. Variations in influenza vaccination among the elderly. Am J Health Behav. 2004;28:352–60.PubMedCrossRef
40.
Zurück zum Zitat Hoover DR, Sambamoorthi U, Crystal S. Characteristics of community dwelling elderly not vaccinated for pneumococcus in 1998 and 2001. Prev Med. 2004;39:517–27.PubMedCrossRef Hoover DR, Sambamoorthi U, Crystal S. Characteristics of community dwelling elderly not vaccinated for pneumococcus in 1998 and 2001. Prev Med. 2004;39:517–27.PubMedCrossRef
41.
Zurück zum Zitat Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged >or =65 years–United States, 2001. JAMA. 2002;288:2815–7.CrossRef Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged >or =65 years–United States, 2001. JAMA. 2002;288:2815–7.CrossRef
42.
Zurück zum Zitat Chen JY, Fox SA, Cantrell CH, Stockdale SE, Kagawa-Singer M. Health disparities and prevention: racial/ethnic barriers to flu vaccinations. J Community Health. 2007;32:5–20.PubMedCrossRef Chen JY, Fox SA, Cantrell CH, Stockdale SE, Kagawa-Singer M. Health disparities and prevention: racial/ethnic barriers to flu vaccinations. J Community Health. 2007;32:5–20.PubMedCrossRef
43.
Zurück zum Zitat Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486–93.PubMedCrossRef Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486–93.PubMedCrossRef
44.
Zurück zum Zitat Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005;37:248–51.PubMedCrossRef Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005;37:248–51.PubMedCrossRef
45.
Zurück zum Zitat Gamble HL, Klosky JL, Parra GR, Randolph ME: Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol. 2009. Gamble HL, Klosky JL, Parra GR, Randolph ME: Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol. 2009.
Metadaten
Titel
Factors influencing the willingness of US women to vaccinate their daughters against the human papillomavirus to prevent cervical cancer
verfasst von
Jennifer Y. Lai
Anna V. Tinker
Winson Y. Cheung
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0582-z

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.